한글목차

세계 아카시아 치료 시장 전망은 병원, 소매 약국, 온라인 약국 시장의 기회로 인해 유망합니다. 세계 아카시아 치료 시장은 2025-2031년 연평균 복합 성장률(CAGR) 5.1%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 식도 운동 장애의 유병률 증가, 비침습적 치료 옵션에 대한 수요 증가, 위장 건강에 대한 인식 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 칼슘 채널 차단제가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 병원이 가장 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

아카시아 치료 시장의 새로운 트렌드

아카시아 치료 시장은 현재 진행 중인 연구와 보다 효과적이고 덜 침습적이며 맞춤 치료법에 대한 요구로 인해 큰 변화의 시기를 맞이하고 있습니다. 이러한 새로운 경향은 임상 진료를 재구성하고, 만성 식도 질환을 앓고 있는 환자들의 예후를 개선하고 있습니다.

• 저침습 내시경 기술: Peroral Endoscopic Myotomy(POEM)를 필두로 점점 더 정교해지는 새로운 저침습 내시경 시술에 대한 강한 추세가 있습니다. 이러한 시술은 회복 시간 단축, 합병증 감소, 기존 수술에 버금가는 효과를 가져와 환자나 임상의에게 매우 매력적입니다.
• 개인화된 치료 알고리즘: 아카시아의 아형(Chicago Classification)과 환자 개개인의 특성에 따라 개인화된 치료 알고리즘을 개발하는 방향으로 트렌드가 변화하고 있습니다. 이 접근법은 특정 근육 절개 길이 및 확장 프로토콜과 같은 중재 방법을 조정하여 장기적인 증상 완화 및 환자별 결과를 최적화하는 것을 목표로 합니다.
• 신규 약리학적 약제: 식도의 염증과 신경재생을 표적으로 하는 생물학적 치료 등 기존의 칼슘길항제나 질산제에 국한되지 않는 새로운 약리학적 약제에 대한 연구가 진행되고 있습니다. 이러한 추세는 아카시아의 근본적인 병태생리를 해결하려는 시도이며, 향후 보다 덜 침습적이거나 병태생리를 조절하는 치료법을 제공할 수 있을 것으로 보입니다.
• 고급 진단법: 고해상도 마노메트리(HRM)와 임피던스 및 기능적 내강 영상 프로브(FLIP)와 같은 고급 진단 양식의 통합은 새로운 트렌드입니다. 이러한 정교한 도구는 식도 운동과 하부 식도 괄약근의 기능을 보다 정확하게 파악하여 치료법 선택과 수술의 성공 여부를 보다 정확하게 평가할 수 있는 지침이 될 수 있습니다.
• 장기 결과 데이터 및 등록: 아카시아 치료에서 확실한 장기 결과 데이터 수집과 국내/국제 등록의 확립이 점점 더 중요해지고 있습니다. 이러한 추세는 다양한 치료법의 내구성과 안전성을 비교하고, 임상 가이드라인에 정보를 제공하고, 향후 치료 전략에 대한 근거에 기반한 의사결정을 지원하는 데 있어 매우 중요합니다.

이러한 추세는 보다 침습적이고 정확한 치료를 촉진하고, 환자 맞춤형 치료를 가능하게 하며, 새로운 약물 치료의 탐색을 촉진하고, 진단 정확도를 높이고, 장기적인 치료 성공을 위한 보다 견고한 증거 기반을 확립함으로써 아카시아 치료 시장을 크게 재편하고 있습니다. 이를 통해 궁극적으로 환자의 삶의 질 향상을 목표로 하고 있습니다.

아카시아 치료 시장의 최근 동향

아카시아 치료 시장은 보다 효과적이고 덜 침습적이며 환자 중심의 치료법에 대한 지속적인 탐구를 주요 원동력으로 삼아 최근 몇 가지 중요한 트렌드를 목격하게 되었습니다. 이러한 발전은 식도 운동 장애라는 난제를 해결하는 데 큰 변화를 가져오고 있습니다.

• POEM의 보급: 중요한 진전은 경구 내시경적 근절개술(POEM)의 전 세계적인 보급과 개선입니다. 이 저침습적 내시경 치료는 기존의 외과적 근절개술에 비해 연하장애 완화 효과가 높고 회복이 빨라 1차적 치료법으로 주목받고 있습니다.
• 로봇 보조 헬러 근층 절개술: 최근 로봇 보조 복강경 헬러 근층 절개술의 사용이 증가하고 있습니다. 로봇 수술은 외과의사에게 정밀성, 손재주, 시각성을 향상시키고, 특히 복잡한 아칼라시아 사례에서 환자의 예후를 개선하고 수술 합병증을 감소시킬 수 있습니다.
• 공기압 팽창술의 강화: 공기압 팽창술의 개발은 풍선 크기, 팽창 압력, 시술 방법의 개선에 중점을 두어 치료 결과를 최적화하고 천공과 같은 합병증의 위험을 줄이는 것을 목표로 합니다. 단계적 확대가 일반화되고 있으며, 완만하고 지속적인 완화를 목표로 하고 있습니다.
• 진단 정확도 향상: 진단 도구의 진화, 특히 시카고 분류(Chicago Classification)의 업데이트에 따른 고해상도 마노메트리(HRM)를 통해 아카시아의 아형을 보다 정확하게 분류할 수 있게 되었습니다. 이러한 진단 정확도 향상은 치료 선택에 대한 지침이 되고, 환자에게 보다 맞춤화된 효과적인 개입으로 이어질 수 있습니다.
• 병용요법의 등장: 다양한 치료법(예: 보툴리눔툭신(보톡스) 주사와 공기 확장술의 병용, 헬러근 절개술 후 재발에 대한 POEM 등)을 사용하여 최적의 증상 완화를 달성하고 난치성 질환을 치료하기 위한 병용요법의 연구와 사용이 증가하고 있으며, 이는 보다 개별화된 접근법을 반영합니다.

이러한 시장 동향은 최소침습적이면서도 매우 효과적인 시술의 촉진, 수술 정확도 향상, 개인별 맞춤 치료를 위한 진단 계층화 개선, 유연한 병용 전략 제공 등 아카시아 치료 시장에 종합적인 영향을 미치고 있습니다. 이를 통해 환자의 예후를 개선하고 아카시아 환자의 삶의 질을 향상시킬 수 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 이완불능증 치료 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• 칼슘 채널 차단제 : 동향과 예측(2019-2031년)
• Nifedipine : 동향과 예측(2019-2031년)
• 보툴리눔톡신(보톡스) 주사 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 세계의 이완불능증 치료 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원 : 동향과 예측(2019-2031년)
• 소매 약국 : 동향과 예측(2019-2031년)
• 온라인 약국 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 이완불능증 치료 시장 : 지역별

제7장 북미의 이완불능증 치료 시장

• 개요
• 북미의 이완불능증 치료 시장 : 유형별
• 북미의 이완불능증 치료 시장 : 용도별
• 미국의 이완불능증 치료 시장
• 멕시코의 이완불능증 치료 시장
• 캐나다의 이완불능증 치료 시장

제8장 유럽의 이완불능증 치료 시장

• 개요
• 유럽의 이완불능증 치료 시장 : 유형별
• 유럽의 이완불능증 치료 시장 : 용도별
• 독일의 이완불능증 치료 시장
• 프랑스의 이완불능증 치료 시장
• 스페인의 이완불능증 치료 시장
• 이탈리아의 이완불능증 치료 시장
• 영국의 이완불능증 치료 시장

제9장 아시아태평양의 이완불능증 치료 시장

• 개요
• 아시아태평양의 이완불능증 치료 시장 : 유형별
• 아시아태평양의 이완불능증 치료 시장 : 용도별
• 일본의 이완불능증 치료 시장
• 인도의 이완불능증 치료 시장
• 중국의 이완불능증 치료 시장
• 한국의 이완불능증 치료 시장
• 인도네시아의 이완불능증 치료 시장

제10장 기타 지역(ROW)의 이완불능증 치료 시장

• 개요
• 기타 지역 의 이완불능증 치료 시장 : 유형별
• 기타 지역 의 이완불능증 치료 시장 : 용도별
• 중동의 이완불능증 치료 시장
• 남미의 이완불능증 치료 시장
• 아프리카의 이완불능증 치료 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 이완불능증 치료 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 인수합병(M&A), 계약, 제휴 및 합작투자(JV)

제13장 밸류체인 주요 기업 개요

• 경쟁 분석
• Bausch Health
• Pfizer
• Accord HealthCare
• AdvaCare Pharma
• Merz Therapeutics
• Galderma
• Zydus Pharmaceuticals

제14장 부록

• 그림 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global achalasia treatment market looks promising with opportunities in the hospital, retail pharmacy, and online pharmacy markets. The global achalasia treatment market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of esophageal motility disorders, the rising demand for noninvasive treatment options, and the growing awareness about gastrointestinal health.

• Lucintel forecasts that, within the type category, calcium channel blocker is expected to witness the highest growth over the forecast period.
• Within the application category, hospital is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Achalasia Treatment Market

The achalasia treatment market is undergoing significant transformation, driven by ongoing research and a desire for more effective, less invasive, and personalized therapeutic approaches. These emerging trends are reshaping clinical practice and improving outcomes for patients suffering from this chronic esophageal disorder.

• Minimally Invasive Endoscopic Techniques: There's a strong trend towards increasingly refined and novel minimally invasive endoscopic techniques, with Peroral Endoscopic Myotomy (POEM) leading the way. These procedures offer reduced recovery times, fewer complications, and comparable efficacy to traditional surgery, making them highly attractive to both patients and clinicians.
• Personalized Treatment Algorithms: The trend is shifting towards developing personalized treatment algorithms based on achalasia subtypes (Chicago Classification) and individual patient characteristics. This approach aims to tailor interventions, such as specific myotomy lengths or dilation protocols, for optimal long-term symptom relief and better patient-specific outcomes.
• Novel Pharmacological Agents: Research is exploring novel pharmacological agents beyond traditional calcium channel blockers and nitrates, including biological therapies targeting esophageal inflammation or nerve regeneration. This trend seeks to address the underlying pathophysiology of achalasia, potentially offering less invasive or even disease-modifying treatments in the future.
• Advanced Diagnostic Modalities: The integration of advanced diagnostic modalities like high-resolution manometry (HRM) with impedance and functional lumen imaging probe (FLIP) is an emerging trend. These sophisticated tools provide more precise insights into esophageal motility and lower esophageal sphincter function, guiding treatment selection and assessing procedural success with greater accuracy.
• Long-Term Outcome Data and Registries: There's an increasing emphasis on collecting robust long-term outcome data and establishing national/international registries for achalasia treatments. This trend is crucial for comparing the durability and safety of different interventions, informing clinical guidelines, and supporting evidence-based decision-making for future therapeutic strategies.

These trends are profoundly reshaping the achalasia treatment market by promoting less invasive and more precise interventions, enabling personalized patient care, driving the search for novel drug therapies, enhancing diagnostic accuracy, and establishing a stronger evidence base for long-term treatment success. This ultimately aims for improved patient quality of life.

Recent Developments in the Achalasia Treatment Market

The achalasia treatment market has recently seen several crucial developments, largely driven by a continuous quest for more effective, less invasive, and patient-centric therapeutic options. These advancements are transforming the management of this challenging esophageal motility disorder.

• Widespread Adoption of POEM: A significant development is the increasing widespread adoption and refinement of Peroral Endoscopic Myotomy (POEM) globally. This minimally invasive endoscopic procedure has become a prominent first-line treatment due to its effectiveness in relieving dysphagia and its faster recovery compared to traditional surgical myotomy.
• Robot-Assisted Heller Myotomy: Recent advancements include the increased use of robot-assisted laparoscopic Heller myotomy. Robotics offer enhanced precision, dexterity, and visualization for surgeons, potentially leading to improved patient outcomes and reduced operative complications, particularly in complex cases of achalasia.
• Enhanced Pneumatic Dilation Techniques: Developments in pneumatic dilation focus on refining balloon sizes, inflation pressures, and procedural techniques to optimize outcomes and reduce the risk of complications like perforation. Graded dilations are becoming more common, aiming for gradual and sustained relief.
• Improved Diagnostic Accuracy: The evolution of diagnostic tools, especially high-resolution manometry (HRM) with Chicago Classification updates, has allowed for more precise subtyping of achalasia. This improved diagnostic accuracy guides treatment selection, leading to more tailored and effective interventions for patients.
• Emergence of Combination Therapies: There's growing exploration and use of combination therapies, where different treatment modalities (e.g., botulinum toxin injection followed by pneumatic dilation, or POEM for recurrence after Heller myotomy) are employed to achieve optimal symptom relief or manage refractory cases, reflecting a more individualized approach.

These developments are collectively impacting the achalasia treatment market by promoting less invasive yet highly effective procedures, enhancing surgical precision, improving diagnostic stratification for personalized treatment, and offering flexible combination strategies. This leads to better patient outcomes and an improved quality of life for achalasia sufferers.

Strategic Growth Opportunities in the Achalasia Treatment Market

The achalasia treatment market presents significant strategic growth opportunities across key applications, driven by the increasing incidence of the disorder and continuous advancements in therapeutic approaches. Capitalizing on these application-specific demands will be vital for market players to expand their footprint and innovate.

• Minimally Invasive Procedures Expansion: Expanding the reach and accessibility of minimally invasive endoscopic procedures like POEM is a major growth opportunity. Investing in training programs for gastroenterologists and surgeons, and developing next-generation endoscopic tools, can drive adoption in new regions and healthcare settings.
• Drug Development for Symptom Management: There is a significant opportunity in developing novel pharmacological agents for long-term symptom management or as bridge therapy, especially for patients unsuitable for invasive procedures. This addresses an unmet need for non-interventional solutions or adjuncts to existing treatments.
• Diagnostic Tools Enhancement: Growth lies in innovating and disseminating advanced diagnostic tools, particularly next-generation high-resolution manometry systems and functional lumen imaging probes (FLIP). Precise diagnosis is crucial for appropriate treatment selection, and improved tools can differentiate achalasia subtypes, leading to better outcomes.
• Pediatric Achalasia Treatment: The pediatric segment represents a niche but important growth opportunity. Developing and refining treatment approaches, instruments, and protocols specifically tailored for children with achalasia, considering their unique anatomical and physiological needs, can address a critical unmet clinical demand.
• Post-Treatment Management and Monitoring: Strategic growth can be found in developing solutions for post-treatment management and long-term monitoring of achalasia patients. This includes digital health solutions for symptom tracking, dietary guidance, and identifying recurrence early, improving patient quality of life and ensuring sustained therapeutic success.

These strategic growth opportunities are profoundly impacting the achalasia treatment market by fostering innovation in less invasive techniques, driving pharmaceutical research, improving diagnostic precision, addressing specific patient demographics, and extending care beyond the initial procedure. This holistic approach promises to enhance patient outcomes and broaden market scope.

Achalasia Treatment Market Driver and Challenges

The achalasia treatment market's trajectory is shaped by various technological, economic, and regulatory factors. Major drivers include the rising global incidence of achalasia and advancements in minimally invasive techniques, while challenges encompass the high cost of advanced procedures, lack of awareness, and the complexity of diagnosis.

The factors responsible for driving the achalasia treatment market include:

1. Rising Incidence of Achalasia: The increasing global prevalence and incidence of achalasia, although a rare disease, contributes significantly to market growth. As more cases are diagnosed, the demand for effective treatment options, ranging from medications to advanced surgical and endoscopic procedures, naturally rises across all regions.

2. Advancements in Minimally Invasive Techniques: The continuous development and widespread adoption of minimally invasive procedures like Peroral Endoscopic Myotomy (POEM) and robot-assisted Heller myotomy are key drivers. These techniques offer improved patient outcomes, shorter recovery times, and reduced morbidity compared to traditional surgery, boosting their market appeal.

3. Improved Diagnostic Technologies: The evolution of diagnostic tools, especially high-resolution manometry (HRM) with detailed Chicago Classification, has enhanced the accuracy and subtyping of achalasia. This leads to earlier and more precise diagnoses, enabling timely intervention and contributing to the overall expansion of the treatment market.

4. Increasing Healthcare Expenditure: Growing healthcare expenditure globally, particularly in emerging economies, contributes to better access to specialized medical facilities and advanced treatment options for achalasia. Increased investment allows for the adoption of newer technologies and procedures, driving market growth.

5. Growing Awareness among Physicians and Patients: Enhanced awareness of achalasia symptoms among primary care physicians and patients leads to earlier referral and diagnosis. This heightened understanding of the condition and its treatment options fosters demand for both diagnostic tools and subsequent therapeutic interventions.

Challenges in the achalasia treatment market are:

1. High Cost of Advanced Procedures: The cost of advanced achalasia treatments, such as POEM and robot-assisted Heller myotomy, can be significantly high. This poses a major challenge, particularly in regions with limited healthcare budgets or inadequate insurance coverage, restricting patient access to optimal care.

2. Lack of Awareness in Underserved Areas: Despite increasing overall awareness, a significant challenge remains in rural and underserved areas where achalasia symptoms may be misdiagnosed or dismissed. This lack of awareness among both patients and local healthcare providers delays diagnosis and appropriate treatment, limiting market penetration.

3. Limited Availability of Skilled Professionals: Advanced procedures like POEM require highly specialized training and expertise, and there is a limited number of gastroenterologists and surgeons proficient in these techniques globally. This scarcity of skilled professionals can restrict the widespread adoption and availability of these treatments.

4. The overall impact of these drivers and challenges on the achalasia treatment market is a dynamic tension between the promise of innovative, less invasive therapies and the hurdles of access, cost, and specialized expertise. While drivers propel market growth by improving outcomes and expanding options, challenges necessitate strategic investments in training, awareness, and cost-effective solutions to ensure equitable access to care.

These drivers and challenges on the achalasia treatment market is a dynamic tension between the promise of innovative, less invasive therapies and the hurdles of access, cost, and specialized expertise. While drivers propel market growth by improving outcomes and expanding options, challenges necessitate strategic investments in training, awareness, and cost-effective solutions to ensure equitable access to care.

List of Achalasia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies achalasia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the achalasia treatment companies profiled in this report include-

• Bausch Health
• Pfizer
• Accord HealthCare
• AdvaCare Pharma
• Merz Therapeutics
• Galderma
• Zydus Pharmaceuticals

Achalasia Treatment Market by Segment

The study includes a forecast for the global achalasia treatment market by type, application, and region.

Achalasia Treatment Market by Type [Value from 2019 to 2031]:

• Calcium Channel Blockers
• Nifedipine
• Botulinum Toxin Injection
• Others

Achalasia Treatment Market by Application [Value from 2019 to 2031]:

• Hospitals
• Retail Pharmacy
• Online Pharmacy
• Others

Achalasia Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Achalasia Treatment Market

The achalasia treatment market is witnessing significant advancements, driven by the increasing prevalence of this rare esophageal motility disorder and a push towards less invasive and more effective therapeutic options. Recent developments focus on refining existing procedures like POEM and Heller myotomy, alongside exploring novel pharmacological and endoscopic interventions. This evolution aims to improve long-term symptom relief and enhance the overall quality of life for patients.

• United States: The US market leads in adopting advanced endoscopic procedures like Peroral Endoscopic Myotomy (POEM) and robot-assisted Heller myotomy, driven by strong research and development, high healthcare expenditure, and favorable reimbursement policies. There's a focus on achieving long-term symptom control and minimizing complications for achalasia patients.
• China: China is rapidly expanding its capabilities in achalasia treatment, with increasing adoption of POEM and pneumatic dilation in major hospitals. Growth is propelled by a large patient base, improving healthcare infrastructure, and a growing number of trained endoscopists, making advanced treatments more accessible across the country.
• Germany: Germany achalasia treatment market emphasizes evidence-based practices and high-quality surgical and endoscopic interventions. There's a strong focus on precise diagnostics using high-resolution manometry and a preference for established procedures like Heller myotomy and pneumatic dilation, with increasing interest in POEM's long-term outcomes.
• India: India achalasia treatment market is witnessing significant growth, driven by increasing awareness, improving diagnostic capabilities, and the rising availability of endoscopic and surgical expertise. Cost-effectiveness is a key factor, with pneumatic dilation and POEM gaining traction in metropolitan and tier-two cities.
• Japan: Japan is a pioneer in endoscopic myotomy, particularly POEM, which originated here. The market is characterized by widespread adoption of POEM as a first-line treatment, supported by extensive clinical experience, advanced endoscopic technology, and a focus on minimally invasive procedures for improved patient recovery.

Features of the Global Achalasia Treatment Market

• Market Size Estimates: Achalasia treatment market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Achalasia treatment market size by type, application, and region in terms of value ($B).
• Regional Analysis: Achalasia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the achalasia treatment market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the achalasia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the achalasia treatment market by type (calcium channel blockers, nifedipine, botulinum toxin injection, and others), application (hospitals, retail pharmacy, online pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Achalasia Treatment Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Calcium Channel Blockers: Trends and Forecast (2019-2031)
• 4.4 Nifedipine: Trends and Forecast (2019-2031)
• 4.5 Botulinum Toxin Injection: Trends and Forecast (2019-2031)
• 4.6 Others: Trends and Forecast (2019-2031)

5. Global Achalasia Treatment Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Retail Pharmacy: Trends and Forecast (2019-2031)
• 5.5 Online Pharmacy: Trends and Forecast (2019-2031)
• 5.6 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Achalasia Treatment Market by Region

7. North American Achalasia Treatment Market

• 7.1 Overview
• 7.2 North American Achalasia Treatment Market by Type
• 7.3 North American Achalasia Treatment Market by Application
• 7.4 United States Achalasia Treatment Market
• 7.5 Mexican Achalasia Treatment Market
• 7.6 Canadian Achalasia Treatment Market

8. European Achalasia Treatment Market

• 8.1 Overview
• 8.2 European Achalasia Treatment Market by Type
• 8.3 European Achalasia Treatment Market by Application
• 8.4 German Achalasia Treatment Market
• 8.5 French Achalasia Treatment Market
• 8.6 Spanish Achalasia Treatment Market
• 8.7 Italian Achalasia Treatment Market
• 8.8 United Kingdom Achalasia Treatment Market

9. APAC Achalasia Treatment Market

• 9.1 Overview
• 9.2 APAC Achalasia Treatment Market by Type
• 9.3 APAC Achalasia Treatment Market by Application
• 9.4 Japanese Achalasia Treatment Market
• 9.5 Indian Achalasia Treatment Market
• 9.6 Chinese Achalasia Treatment Market
• 9.7 South Korean Achalasia Treatment Market
• 9.8 Indonesian Achalasia Treatment Market

10. ROW Achalasia Treatment Market

• 10.1 Overview
• 10.2 ROW Achalasia Treatment Market by Type
• 10.3 ROW Achalasia Treatment Market by Application
• 10.4 Middle Eastern Achalasia Treatment Market
• 10.5 South American Achalasia Treatment Market
• 10.6 African Achalasia Treatment Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Achalasia Treatment Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Bausch Health
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Pfizer
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Accord HealthCare
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 AdvaCare Pharma
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Merz Therapeutics
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Galderma
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Zydus Pharmaceuticals
  • Company Overview
  • Achalasia Treatment Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us